One of the world's leading centers for nasopharyngeal carcinoma (NPC) — the "Canton tumor" — in a top-ranked comprehensive cancer center.
Hospital Credentials
Grade A Tertiary Oncology Hospital
Founded 1964; 2,245 beds; 2.56 million outpatient visits and 222,000 admissions per year.
Fudan A+++ · Oncology No. 2
2023 China Hospital Rankings; repeatedly awarded the highest grade (A) in national tertiary public hospital assessment.
International Medical Center
SYSUCC International Medical Center opened July 2026; sister institution of U.S. No. 1 M.D. Anderson Cancer Center.
Academic Standing
Top Faculty
3 CAS Members, 3 CAE Members, 47 national-level talents; 231 doctoral supervisors and 334 master's supervisors.
National Research Platforms
State Key Laboratory of South China Malignant Tumor Prevention and Treatment; National New Drug (Anticancer Drug) Clinical Trial Research Center.
Global Guideline Impact
92+ frontline findings adopted by international standards; NPC results incorporated into NCCN, ESMO and ASCO guidelines.
The Nasopharyngeal Department
Five-Ones Key Department
Guangdong Provincial "Five Ones Project" Key Department; NPC has been a central focus since 1964.
Expert Team
24 senior physicians, 8 doctoral supervisors, 12 master's supervisors; dedicated NPC laboratory, serum bank and endoscopy suite.
Full-Spectrum NPC Care
Epidemiology, early diagnosis, radiotherapy, drug therapy, surgery and psychological rehabilitation — stage-specific MDT treatment.
Core Technologies
Definitive IMRT for NPC
Asia-leading radiotherapy center; intensity-modulated radiotherapy with better target conformity and normal-tissue protection.
Toxicity-Reduction Technique
Prospective phase III trial (568 patients) sparing medial retropharyngeal nodes — reduced dysphagia for 99% of NPC patients (published in The BMJ, 2023).
TPF Induction Chemotherapy
Raised 3-year overall survival from 86% to 92% across 10 centers; reshaped NCCN and ESMO guidelines (Lancet Oncology).
AI-Precision Radiotherapy
AI-based NPC radiotherapy planning produces a plan in 3.5 minutes — faster and better.
Recurrent/Residual NPC Surgery
Minimally invasive and endoscopic surgery for selected recurrent cases; endoscopic microwave coagulation for post-radiotherapy recurrence.
Novel Drug Therapy
Innovative clinical trials; metastatic NPC study with >20% 2-year survival improvement (JAMA Oncology).
Conditions Treated
Awards & Milestones
- 1. 2023 STEM Ranking — Oncology No. 1 in China; 2024 Nature Index — 5th among cancer centers worldwide.
- 2. Cancer Communications (IF 24.9, JCR Oncology Q1) — English-language journal published by SYSUCC.
- 3. 1962: first international histopathological classification of NPC; 1992: "92 staging system"; 2002: familial NPC gene in Nature Genetics.
- 4. 76 provincial/ministerial+ awards as first institution, including 2 National Natural Science Awards (2nd Class) and 6 National S&T Progress Awards (2nd Class).
Address & Contact
Yuexiu Campus (Main)
No. 651 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong, China.
Huangpu Campus
No. 1 Kaiyang 5th Road, Sino-Singapore Guangzhou Knowledge City, Huangpu District, Guangzhou.
International Services
SYSUCC International Medical Center — one-stop service for international patients. Website: www.sysucc.org.cn.